JP2014527042A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527042A5
JP2014527042A5 JP2014522877A JP2014522877A JP2014527042A5 JP 2014527042 A5 JP2014527042 A5 JP 2014527042A5 JP 2014522877 A JP2014522877 A JP 2014522877A JP 2014522877 A JP2014522877 A JP 2014522877A JP 2014527042 A5 JP2014527042 A5 JP 2014527042A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acute lymphoblastic
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014522877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527042A (ja
JP6027110B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/047100 external-priority patent/WO2013016081A1/en
Publication of JP2014527042A publication Critical patent/JP2014527042A/ja
Publication of JP2014527042A5 publication Critical patent/JP2014527042A5/ja
Application granted granted Critical
Publication of JP6027110B2 publication Critical patent/JP6027110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014522877A 2011-07-27 2012-07-18 ノッチ経路シグナリングインヒビター化合物 Active JP6027110B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US61/512,016 2011-07-27
US201161560486P 2011-11-16 2011-11-16
US61/560,486 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (3)

Publication Number Publication Date
JP2014527042A JP2014527042A (ja) 2014-10-09
JP2014527042A5 true JP2014527042A5 (enExample) 2015-08-20
JP6027110B2 JP6027110B2 (ja) 2016-11-16

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014522877A Active JP6027110B2 (ja) 2011-07-27 2012-07-18 ノッチ経路シグナリングインヒビター化合物

Country Status (36)

Country Link
US (1) US8569286B2 (enExample)
EP (1) EP2736920B1 (enExample)
JP (1) JP6027110B2 (enExample)
KR (1) KR101578309B1 (enExample)
CN (1) CN103732612B (enExample)
AP (1) AP4080A (enExample)
AR (1) AR087107A1 (enExample)
AU (1) AU2012287251B2 (enExample)
BR (1) BR112014001600B1 (enExample)
CA (1) CA2841178C (enExample)
CL (1) CL2014000175A1 (enExample)
CO (1) CO6862159A2 (enExample)
CR (1) CR20140036A (enExample)
CY (1) CY1116645T1 (enExample)
DK (1) DK2736920T3 (enExample)
DO (1) DOP2014000011A (enExample)
EA (1) EA023044B1 (enExample)
EC (1) ECSP14013179A (enExample)
ES (1) ES2544937T3 (enExample)
GT (1) GT201400012A (enExample)
HR (1) HRP20150771T1 (enExample)
HU (1) HUE027534T2 (enExample)
IL (1) IL229988A (enExample)
JO (1) JO3148B1 (enExample)
MA (1) MA35611B1 (enExample)
ME (1) ME02171B (enExample)
MX (1) MX356536B (enExample)
MY (1) MY184303A (enExample)
PE (1) PE20141061A1 (enExample)
PH (1) PH12014500215B1 (enExample)
PL (1) PL2736920T3 (enExample)
PT (1) PT2736920E (enExample)
RS (1) RS54135B1 (enExample)
SI (1) SI2736920T1 (enExample)
TW (1) TWI568730B (enExample)
WO (1) WO2013016081A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350216B2 (en) 2013-01-14 2019-07-16 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
AU2017249078B2 (en) * 2016-04-12 2022-10-20 Eli Lilly And Company Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
MX380780B (es) * 2016-04-12 2025-03-12 Lilly Co Eli TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN109562114A (zh) * 2016-08-31 2019-04-02 伊莱利利公司 用于治疗实体瘤的给药方案
CA3039405A1 (en) 2016-10-12 2018-04-19 Eli Lilly And Company Targeted treatment of mature t-cell lymphoma
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
CN110461335A (zh) 2017-02-17 2019-11-15 弗雷德哈钦森癌症研究中心 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
US12193994B2 (en) * 2017-11-06 2025-01-14 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
AU2019266150A1 (en) * 2018-05-06 2021-01-07 Ayala Pharmaceuticals Inc. Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
SG11202111191YA (en) 2019-04-08 2021-11-29 Frequency Therapeutics Inc Combination of chir99021 and valproic acid for treating hearing loss
US11999750B2 (en) 2022-01-12 2024-06-04 Denali Therapeutics Inc. Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
CA2325389A1 (en) * 1998-06-22 1999-12-29 James E. Audia Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
HRP20050663A2 (en) 2003-02-04 2006-12-31 F. Hoffmann - La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
AU2004270361B2 (en) 2003-09-09 2009-06-25 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
WO2005040126A1 (en) 2003-10-06 2005-05-06 F. Hoffman-La Roche Ag Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
KR101169628B1 (ko) 2006-03-27 2012-07-30 에프. 호프만-라 로슈 아게 감마 세크레테아제 저해제로서의 말론아미드 유도체
WO2008092786A1 (en) * 2007-02-02 2008-08-07 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
KR20100101624A (ko) 2008-01-11 2010-09-17 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Similar Documents

Publication Publication Date Title
JP2014527042A5 (enExample)
JP2020511467A5 (enExample)
ME02171B (me) Spoj za inhibiciju notch signalnog puta
JP2013509429A5 (enExample)
JP2015536964A5 (enExample)
JP2014509653A5 (enExample)
JP2017519027A5 (enExample)
JP2014502638A5 (enExample)
JP2013237682A5 (enExample)
JP2015500331A5 (enExample)
JP2018024682A5 (enExample)
JP2015509536A5 (enExample)
JP2012255026A5 (enExample)
JP2015508103A5 (enExample)
HRP20171151T1 (hr) Inhibitori cdc7
HRP20231163T1 (hr) Prolijekovi glutaminskih analoga
JP2017525730A5 (enExample)
PH12012502142A1 (en) Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities
HRP20202065T1 (hr) Kristalni oblik inhibitora mdm2
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2013522232A5 (enExample)
HRP20210681T1 (hr) Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida
JP2015522037A5 (enExample)
JP2012516344A5 (enExample)
JP2012526766A5 (enExample)